Log in to save to my catalogue

Tumor mutational burden assessment and standardized bioinformatics approach using custom NGS panels...

Tumor mutational burden assessment and standardized bioinformatics approach using custom NGS panels...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_38a817e5035043189c5b339051b10be7

Tumor mutational burden assessment and standardized bioinformatics approach using custom NGS panels in clinical routine

Publication information

Publisher

England: BioMed Central Ltd

More information

Scope and Contents

Contents

High tumor mutational burden (TMB) was reported to predict the efficacy of immune checkpoint inhibitors (ICIs). Pembrolizumab, an anti-PD-1, received FDA-approval for the treatment of unresectable/metastatic tumors with high TMB as determined by the FoundationOne®CDx test. It remains to be determined how TMB can also be calculated using other tests...

Alternative Titles

Full title

Tumor mutational burden assessment and standardized bioinformatics approach using custom NGS panels in clinical routine

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_38a817e5035043189c5b339051b10be7

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_38a817e5035043189c5b339051b10be7

Other Identifiers

ISSN

1741-7007

E-ISSN

1741-7007

DOI

10.1186/s12915-024-01839-8

How to access this item